Search hospitals
>
Minnesota
>
Minneapolis
Hennepin County Medical Center
Claim this profile
Minneapolis, Minnesota 55415
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
682 reported clinical trials
24 medical researchers
Summary
Hennepin County Medical Center is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Hennepin County Medical Center is involved with conducting 682 clinical trials across 775 conditions. There are 24 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Area of expertise
Breast Cancer
Hennepin County Medical Center has run 98 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Hennepin County Medical Center has run 80 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
David M. King
Park Nicollet Clinic - Saint Louis Park
9 years of reported clinical research
Daniel M. Anderson
Abbott-Northwestern Hospital
7 years of reported clinical research
Yan Ji
Regions Hospital
2 years of reported clinical research
Pamala A. Pawloski
Park Nicollet Clinic - Saint Louis Park
6 years of reported clinical research
Clinical Trials running at Hennepin County Medical Center
Lung Cancer
Prostate Cancer
Breast Cancer
Breast cancer
Cancer
Esophageal cancer
Kidney Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Sigvotatug Vedotin + Pembrolizumab
for Non-Small Cell Lung Cancer
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab. Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.
Recruiting
2 awards
Phase 3
6 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Hennepin County Medical Center?
Hennepin County Medical Center is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Hennepin County Medical Center is involved with conducting 682 clinical trials across 775 conditions. There are 24 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Hennepin County Medical Center located?
**Hennepin County Medical Center Location and Parking:** - Located at 701 Park Avenue, downtown Minneapolis. - Accessible via Blue or Green Light Rail line to the Government Plaza station, a 4-minute walk away. - Parking available at HCMC Parking Ramp (6th Street and Park Avenue) or Hospital Parking Ramp (8th Street and Chicago Avenue).
Who should I call to ask about financial aid or insurance network?
**Financial Assistance at Hennepin County Medical Center:** - For guidance with financial assistance, contact Change Healthcare at the Clinic & Specialty Center, Whittier Clinic, or Brooklyn Park Clinic. - For insurance inquiries, call the Customer Service Department at 612-873-3073. - For general billing concerns, also dial 612-873-3073. - For cash, food, or medical assistance, reach out to the EZ Info line at 612-596-1300.
What insurance does Hennepin County Medical Center accept?
Hennepin County Medical Center, known as Hennepin Healthcare, accepts a wide range of insurance plans. This includes Original Medicare, Medicare Advantage plans such as HumanaChoice (PPO), UCare Prime (HMO-POS), and Medica Advantage (PPO), along with all Medicare Supplemental Plans. They also accept numerous commercial plans, including but not limited to Americas PPO, Blue Cross Blue Shield Aware, Cigna LifeSOURCE Transplant [Kidney], HealthPartners/Cigna Alliance, Medica Passport, PreferredOne PPO, UCare Connect, and UnitedHealthcare Plans. It is recommended to contact Hennepin Healthcare directly to verify network participation and plan acceptance.
What awards or recognition has Hennepin County Medical Center received?
Hennepin County Medical Center (HCMC) in Minneapolis, Minnesota, is nationally recognized for its advancements in health equity by the National Committee for Quality Assurance (NCQA). The Hennepin Healthcare Research Institute (HHRI) enhances patient care through research since 1952, concentrating on Acute Care/Trauma, Addiction, Health Services, and Infectious Diseases (HIV/AIDS).
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.